Using whole genome sequencing, a large group of scientists has identified a new genetic cause of progressive myoclonus epilepsy, one of the most devastating forms of epilepsy that emerges in early childhood and can result in early death

The team found that a previously unknown mutation in a potassium ion channel gene - called KCNC1 - was present in 13% of the PME patients and 7% of patients in a secondary cohort.
 The international team - including members from the University of  Helsinki in Finland and the Universities of Melbourne and South  Australia - report their findings in the journal Nature  Genetics.
Progressive myoclonus epilepsies (PME) are severe, rare forms of  epilepsy and frequently arise from hereditary metabolic disorders.  Their core symptoms include epileptic seizures and debilitating  involuntary muscle twitching. Muscle rigidity, unsteadiness and mental  deterioration are often also present.
For the study, the international team recruited 84 patients with PME  of unknown cause and used DNA sequencing to identify potential genetic  causes of the disorder.
 Modern DNA sequencing techniques have revolutionized genetic  research of rare, severe diseases. In this case, the team used the  technology to sequence the protein-coding elements of the human  genome.
They managed to identify genetic causes in nearly a third of the  PME patients (26 patients, 31%).
13% of PME cases had previously unknown mutation of potassium ion channel gene
Remarkably, the team found that a previously unknown mutation in a  potassium ion channel gene - called KCNC1  - was present in 11 (13%) of  the 84 patients and another two (7%) patients in a secondary  cohort.
The authors note that the mutation was a "de novo" mutation -  meaning it was not inherited from the patients' biological parents.
"De novo" or new mutations are errors that occur in cell division or  in the copying of genetic material. They emerge in a germ cell of one  of the parents, or in the fertilized egg. Every person has dozens of  these new mutations, but they rarely cause disease.
The researchers estimate that this mutation occurs in about 1 in  every 5.7 million conceptions, indicating that globally, at least  hundreds of PME patients could have this mutation. 
Corresponding author and principal investigator Professor Anna-Elina  Lehesjoki, from the University of Helsinki and the Folkhälsan Institute  of Genetics in Helsinki, says:
"The mutation site is an example of a 'mutation hotspot' of the  genome - a DNA nucleotide which is more prone for alterations."
The KCNC1 mutation that the team identified stops a potassium ion  channel in brain cells working properly. The channel - called KV3.1 -  plays an important part in signal transmission in the brain.
Ion channels are how cells, including brain cells  and  muscle cells, translate their chemical messages into electrical  signals. 
The cell builds up a concentration of ions inside itself -  different to the concentration in the cell's environment - and this  creates a voltage difference. Then, when the time is right to send a  signal, the cell opens an ion channel, and because of the voltage  difference, ions travel out of the cell, embodying an electrical version of a chemical message.
The researchers suggest the effect of the mutation is to reduce  inhibitory signals - making patients susceptible to epileptic seizures  and myoclonus starting in childhood. The mutation also leads to  degeneration of the cerebellum - a region of the brain that plays an  important role in movement control - and subtle cognitive decline in  some cases.
Drugs that restore function in this ion channel may already exist
Professor Lehesjoki says because the mutation occurs in a  well-known ion channel, there is hope of developing therapy that  can target this.
"There are anti-epileptic drugs in the market that target other  similar ion channels and follow-up research aims to discover a way to  rescue the function of the channel in PME patients," she adds.
In October 2014, Medical News Today  learned how a team  from Johns Hopkins University in Baltimore, MD, has discovered new   clues about conditions that stem from  faulty ion channels, such as cardiac arrhythmias, epilepsy and  Parkinson's disease. The discovery relates to a common protein that the  team says plays a different role than previously thought in the opening  and closing of channels that let ions in and out of cells.
Written by Catharine Paddock PhD


No comments:
Post a Comment